{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:22:29Z","timestamp":1765610549118,"version":"3.38.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The MASCC Oral Agent Teaching Tool (MOATT\u00ae) was developed to address the challenges of patient education and adherence in the context of oral anticancer agents. Despite its evidence-based design and global availability, there is limited documentation on its application in clinical practice and research. This review aims to assess the extent of MOATT usage and evaluate the impact on patient outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A scoping review was conducted following Joanna Briggs Institute and PRISMA-ScR reporting standards. Databases included CINAHL, Embase, PsycInfo, Web of Science, and PubMed. Inclusion criteria were studies published between 2010 and 2023 that used MOATT in clinical practice or research. Two reviewers independently screened and extracted data, with discrepancies resolved by consensus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>Seventeen studies met the inclusion criteria, from nine countries. The MOATT was most used by nurses and pharmacists to guide patient education when initiating new oral anticancer therapies. Reported outcomes included improved patient knowledge, understanding of medication regimens, and comfort in managing treatments. However, only six studies assessed medication adherence, with mixed results. The tool was adapted in various settings, yet there was a notable lack of detailed reports on its usage and outcomes, highlighting underutilization and potential barriers to broader implementation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The MOATT is a valuable tool for supporting patients on oral anticancer agents yet is underutilized in practice. Future research should focus on understanding the barriers to its adoption, exploring patient and provider perspectives, and integrating implementation science to enhance its use in diverse clinical contexts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09274-3","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:38:31Z","timestamp":1740641911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["15\u00a0years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-7498","authenticated-orcid":false,"given":"Sultan","family":"Kav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-9201","authenticated-orcid":false,"given":"Mapi","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paz","family":"Fern\u00e1ndez-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen F.","family":"Manzullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-1642","authenticated-orcid":false,"given":"Kimberley-Ann","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"DeGennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-4835","authenticated-orcid":false,"given":"Pamela K.","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"1","key":"9274_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents\u2014updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32(1):53. https:\/\/doi.org\/10.1007\/s00520-023-08220-5","journal-title":"Support Care Cancer"},{"issue":"2","key":"9274_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.soncn.2011.02.003","volume":"27","author":"BA Given","year":"2011","unstructured":"Given BA, Spoelstra SL, Grant M (2011) The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs 27(2):93\u2013103. https:\/\/doi.org\/10.1016\/j.soncn.2011.02.003","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"9274_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","volume":"21","author":"JA Greer","year":"2016","unstructured":"Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354\u2013376. https:\/\/doi.org\/10.1634\/theoncologist.2015-0405","journal-title":"Oncologist"},{"issue":"1","key":"9274_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1001\/jamaoncol.2017.0625","volume":"4","author":"JA Zerillo","year":"2018","unstructured":"Zerillo JA, Goldenberg BA, Kotecha RR, Tewari AK, Jacobson JO, Krzyzanowska MK (2018) Interventions to Improve oral chemotherapy safety and quality: a systematic review. JAMA Oncol 4(1):105\u2013117. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0625","journal-title":"JAMA Oncol"},{"key":"9274_CR5","doi-asserted-by":"publisher","unstructured":"Belcher SM, Mackler E, Muluneh B, Ginex PK, Anderson MK, Bettencourt E, DasGupta RK, Elliott J, Hall E, Karlin M, Kostoff D, Marshall VK, Millisor VE, Molnar M, Schneider SM, Tipton J, Yackzan S, LeFebvre KB, Sivakumaran K, . . . Morgan RL (2022) ONS guidelines to support patient adherence to oral anticancer medications. OncolNurs Forum 49(4): 279\u2013295. https:\/\/doi.org\/10.1188\/22.ONF.279-295","DOI":"10.1188\/22.ONF.279-295"},{"issue":"4","key":"9274_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.soncn.2019.06.009","volume":"35","author":"VK Marshall","year":"2019","unstructured":"Marshall VK, Cairns PL (2019) Challenges of caregivers of cancer patients who are on oral oncolytic therapy. Semin Oncol Nurs 35(4):363\u2013369. https:\/\/doi.org\/10.1016\/j.soncn.2019.06.009","journal-title":"Semin Oncol Nurs"},{"key":"9274_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.17925\/EOH.2012.08.02.97","volume":"8","author":"C Rittenberg","year":"2012","unstructured":"Rittenberg C (2012) Meeting educational needs and enhancing adherence of patients receiving oral cancer agents through use of the MASCC oral agent teaching tool. Eur Oncol Haematol 8:97\u2013100. https:\/\/doi.org\/10.17925\/EOH.2012.08.02.97","journal-title":"Eur Oncol Haematol"},{"issue":"5","key":"9274_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00520-009-0692-5","volume":"18","author":"S Kav","year":"2010","unstructured":"Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2010) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 18(5):583\u2013590. https:\/\/doi.org\/10.1007\/s00520-009-0692-5","journal-title":"Support Care Cancer"},{"key":"9274_CR9","doi-asserted-by":"publisher","unstructured":"Kav S, Johnson J, Rittenberg C, Fernadez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Kadmon I, Ami SB, . . . Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16(9): 1075\u20131083. https:\/\/doi.org\/10.1007\/s00520-007-0377-x","DOI":"10.1007\/s00520-007-0377-x"},{"key":"9274_CR10","unstructured":"Rittenberg C, Johnson J, Kav S, Barber L, Lemonde M (2012) MOATT User guide (MASCC, Ed.) https:\/\/mascc.org\/wp-content\/uploads\/2022\/04\/moatt_userguide_sept2016_update_usletter.pdf. Accessed 20 Feb 2025"},{"key":"9274_CR11","unstructured":"Multinational Association of Supportive Care in Cancer (2021) MASCC Oral Agent Teaching Tool (MOATT). https:\/\/mascc.org\/resources\/assessment-tools\/mascc-oral-agent-teaching-tool-moatt\/. Accessed 20 Feb 2025"},{"issue":"1","key":"9274_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E (2018) Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 18(1):143. https:\/\/doi.org\/10.1186\/s12874-018-0611-x","journal-title":"BMC Med Res Methodol"},{"key":"9274_CR13","doi-asserted-by":"publisher","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, . . . Straus SE (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169(7): 467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","DOI":"10.7326\/M18-0850"},{"issue":"1","key":"9274_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK (2010) Scoping studies: advancing the methodology. Implement Sci 5(1):69. https:\/\/doi.org\/10.1186\/1748-5908-5-69","journal-title":"Implement Sci"},{"issue":"12","key":"9274_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jclinepi.2014.03.013","volume":"67","author":"HL Colquhoun","year":"2014","unstructured":"Colquhoun HL, Levac D, O\u2019Brien KK, Straus S, Tricco AC, Perrier L, Kastner M, Moher D (2014) Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol 67(12):1291\u20131294. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.03.013","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"9274_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11124\/jbisrir-2016-2838","volume":"14","author":"MDJ Peters","year":"2016","unstructured":"Peters MDJ (2016) In no uncertain terms: the importance of a defined objective in scoping reviews. JBI Evid Synth 14(2):1\u20134. https:\/\/doi.org\/10.11124\/jbisrir-2016-2838","journal-title":"JBI Evid Synth"},{"key":"9274_CR17","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group, TP (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PloS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"4","key":"9274_CR18","first-page":"302","volume":"24","author":"C Campbell","year":"2014","unstructured":"Campbell C (2014) Nursing intervention to improve adherence and safety with oral cancer therapy. Can Oncol Nurs J 24(4):302\u2013305","journal-title":"Can Oncol Nurs J"},{"issue":"4","key":"9274_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1188\/15.Onf.383-389","volume":"42","author":"J Boucher","year":"2015","unstructured":"Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL (2015) A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncol Nurs Forum 42(4):383\u2013389. https:\/\/doi.org\/10.1188\/15.Onf.383-389","journal-title":"Oncol Nurs Forum"},{"key":"9274_CR20","unstructured":"Bellomo C (2016) Oral Chemotherapy: Patient Education and Nursing Intervention. J Oncol Navig Surviv 7(6):20\u201328. https:\/\/www.jons-online.com\/issues\/2016\/july-2016-vol-7-no-6?view=article&artid=1458:oral-chemotherapy-patient-education-and-nursing-intervention. Accessed 20 Feb 2025"},{"issue":"4","key":"9274_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/apjon.apjon_35_17","volume":"4","author":"G Tokdemir","year":"2017","unstructured":"Tokdemir G, Kav S (2017) The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. Asia Pac J Oncol Nurs 4(4):290\u2013298. https:\/\/doi.org\/10.4103\/apjon.apjon_35_17","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"11","key":"9274_CR22","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1007\/s00520-017-3770-0","volume":"25","author":"C Riese","year":"2017","unstructured":"Riese C, Wei\u00df B, Borges U Jr, Beylich A, Dengler R, Hermes-Moll K, Welslau M, Baumann W (2017) Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial. Support Care Cancer 25(11):3475\u20133483. https:\/\/doi.org\/10.1007\/s00520-017-3770-0","journal-title":"Support Care Cancer"},{"key":"9274_CR23","doi-asserted-by":"publisher","unstructured":"Byrne AE, Redmayne GM, Lam T, Tran J, Chan DK (2018) Implementation and evaluation of a pharmacist-led oral anticancer medication management clinic. J Pharm Pract Res 48(6): 509\u2013515. https:\/\/doi.org\/10.1002\/jppr.1429","DOI":"10.1002\/jppr.1429"},{"key":"9274_CR24","unstructured":"Newman V (2018) Structured patient education and medication adherence in oncology patients prescribed oral chemotherapy 29th international nursing research congress: Innovative global nursing practice and education through research and evidence-based practic. Melbourne. https:\/\/stti.confex.com\/stti\/congrs18\/webprogram\/Paper91579.html. Accessed 20 Feb 2025"},{"issue":"30_suppl","key":"9274_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1200\/JCO.2018.36.30_suppl.254","volume":"36","author":"DA Roberts","year":"2018","unstructured":"Roberts DA, Doolin J, Cibotti C, Hartwell RA, Yenulevich M, Trillo K, Hamdan A, Rodrigues C, Smith MB, Dowling H, Tocci NX, Devlin SM, Shea M, Zerillo JA (2018) Oral chemotherapy education sessions at an academic and community cancer center. J Clin Oncol 36(30_suppl):254\u2013254. https:\/\/doi.org\/10.1200\/JCO.2018.36.30_suppl.254","journal-title":"J Clin Oncol"},{"issue":"14","key":"9274_CR26","first-page":"2531","volume":"33","author":"F He","year":"2019","unstructured":"He F, Shi Z, Xie X (2019) Application of MOATT tool for improving the side effects of Gefitinib Tablets in patients with advanced non-small cell lung cancer. Chin Nurs Res 33(14):2531\u20132534","journal-title":"Chin Nurs Res"},{"issue":"3_suppl","key":"9274_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1078155218823168","volume":"25","author":"R Hartwell","year":"2019","unstructured":"Hartwell R, Cibotti C, Roberts D, Doolin J, Yenulevich M, Trillo K, Smith M, Dowling H, Tocci N, Devlin S, Shea M, Zerillo J (2019) Impact of Pharmacist-Led Oral Antineoplastic Patient Education on Compliance with Quality Oncology Practice Initiative (QOPI) Measures. J Oncol Pharm Pract 25(3_suppl):1\u201324. https:\/\/doi.org\/10.1177\/1078155218823168","journal-title":"J Oncol Pharm Pract"},{"key":"9274_CR28","unstructured":"Tadic D, Djukic Dejanovic S, Djokovic ZITD, Janjic V (2020) The impact of structured education of breast cancer patients receiving capecitabine on mental disorders. J BUON : Official J Balkan Union Oncol 25(1):141\u2013151. http:\/\/europepmc.org\/abstract\/MED\/32277625. Accessed 20 Feb 2025"},{"key":"9274_CR29","doi-asserted-by":"publisher","unstructured":"D\u00fcrr P, Schlichtig K, Kelz C, Deutsch B, Maas R, Eckart MJ, Wilke J, Wagner H, Wolff K, Preu\u00df C, Br\u00fcckl V, Meidenbauer N, Staerk C, Mayr A, Fietkau R, Goebell PJ, Kunath F, Beckmann MW, Mackensen A, . . . Fromm MF (2021) The randomized AMBORA trial: Impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents. J Clin Oncol 39(18): 1983\u20131994. https:\/\/doi.org\/10.1200\/jco.20.03088","DOI":"10.1200\/jco.20.03088"},{"issue":"3","key":"9274_CR30","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.1097\/ncc.0000000000000790","volume":"44","author":"A Tolotti","year":"2021","unstructured":"Tolotti A, Pedrazzani C, Bonetti L, Bianchi M, Valcarenghi D (2021) Patients\u2019 and nurses\u2019 perceptions of the effectiveness of an oral cancer agent education process: a mixed-methods study. Cancer Nurs 44(3):E151-e162. https:\/\/doi.org\/10.1097\/ncc.0000000000000790","journal-title":"Cancer Nurs"},{"issue":"6","key":"9274_CR31","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1177\/1078155220960800","volume":"27","author":"M Lin","year":"2021","unstructured":"Lin M, Hackenyos D, Savidge N, Weidner RA, Murphy-Banks R, Fleckner T, Parsons SK, Rodday AM (2021) Enhancing patients\u2019 understanding of and adherence to oral anticancer medication: Results of a longitudinal pilot intervention. J Oncol Pharm Pract 27(6):1409\u20131421. https:\/\/doi.org\/10.1177\/1078155220960800","journal-title":"J Oncol Pharm Pract"},{"key":"9274_CR32","volume-title":"Oral Chemotherapy Patient Education Using the Multinational Association of Supportive Care in Cancer Oral Agent Teaching Tool Grand Canyon University]","author":"EE Gallagher","year":"2021","unstructured":"Gallagher EE (2021) Oral Chemotherapy Patient Education Using the Multinational Association of Supportive Care in Cancer Oral Agent Teaching Tool Grand Canyon University]. Arizona, Phoenix"},{"issue":"1","key":"9274_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.19193\/0393-6384_2022_1_93","volume":"38","author":"L Wang","year":"2022","unstructured":"Wang L, Zhang J, Xu Y, Xue Q, Meng W (2022) The effects of knowledge-attitude-practice model nursing based on MOATT tool on drug compliance, HHI score, and living quality of lung cancer patients undergoing chemotherapy [Article]. Acta Med Mediterr 38(1):597\u2013602. https:\/\/doi.org\/10.19193\/0393-6384_2022_1_93","journal-title":"Acta Med Mediterr"},{"key":"9274_CR34","doi-asserted-by":"publisher","unstructured":"Fariya S, Mary Martin Daniel PJ, Raj JS, Sureshkumar K, Suthakar M, Muhasaparur Ganesan R (2022) Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India. J Oncol Pharm Pract: 10781552221143065. https:\/\/doi.org\/10.1177\/10781552221143065","DOI":"10.1177\/10781552221143065"},{"issue":"4","key":"9274_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4103\/apjon.apjon_49_17","volume":"4","author":"S Kav","year":"2017","unstructured":"Kav S (2017) Oral agents in cancer treatment: meeting the patients\u2019 needs to ensure medication adherence. Asia Pac J Oncol Nurs 4(4):273\u2013274. https:\/\/doi.org\/10.4103\/apjon.apjon_49_17","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"2","key":"9274_CR36","doi-asserted-by":"publisher","first-page":"e12413","DOI":"10.1111\/ecc.12413","volume":"26","author":"A Arber","year":"2017","unstructured":"Arber A, Odelius A, Williams P, Lemanska A, Faithfull S (2017) Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. Eur J Cancer Care 26(2):e12413. https:\/\/doi.org\/10.1111\/ecc.12413","journal-title":"Eur J Cancer Care"},{"issue":"12","key":"9274_CR37","doi-asserted-by":"publisher","first-page":"e0243309","DOI":"10.1371\/journal.pone.0243309","volume":"15","author":"J P\u00e9richou","year":"2020","unstructured":"P\u00e9richou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, Lazareth A, Karlin L, Beny K, Vantard N, Schwiertz V, Caffin AG, Baudouin A, Sesques P, Brisou G, Ghesqui\u00e8res H, Salles G, Rioufol C (2020) Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients\u2019 knowledge to manage adverse effects. PLoS ONE 15(12):e0243309. https:\/\/doi.org\/10.1371\/journal.pone.0243309","journal-title":"PLoS ONE"},{"issue":"2","key":"9274_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/apjon.apjon_58_20","volume":"8","author":"A Fukawa","year":"2021","unstructured":"Fukawa A (2021) Development of self-management support program for elderly patients with lung cancer receiving molecularly-targeted therapy. Asia Pac J Oncol Nurs 8(2):180\u2013187. https:\/\/doi.org\/10.4103\/apjon.apjon_58_20","journal-title":"Asia Pac J Oncol Nurs"},{"key":"9274_CR39","doi-asserted-by":"publisher","unstructured":"Kunitomo K, Tsumura A, Morishita-Kawahara M, Mikoshiba N (2018) Barriers for an\u00a0implementation of educational program for patients taking oral cancer agents in Japan:\u00a0Consideration of utilization of MOATT. MASCC\/ISOO annual meeting on supportive care in cancer. Vienna. Support Care Cancer 26(Suppl 3):S365\u2013S402. https:\/\/doi.org\/10.1007\/s00520-018-4356-1","DOI":"10.1007\/s00520-018-4356-1"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09274-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:28:07Z","timestamp":1742002087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09274-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9274"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09274-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}